Accordingly, MEX3A-depleted patient-derived CRC tumoroids showed decreased LGR5 expression, accompanied by increased PPARγ expression and higher sensitivity to 5-fluorouracil/oxaliplatin (FOLFOX)-based chemotherapy. The gene discussed is LGR5; the disease is colorectal carcinoma.